Regadenoson: A New Myocardial Stress Agent

Wael Al Jaroudi, Ami E. Iskandrian

Research output: Contribution to journalReview articlepeer-review

171 Scopus citations


Vasodilator stress myocardial perfusion imaging (MPI) accounts for up to 50% of all stress MPI studies performed in the U.S. In 2008, the Food and Drug Administration approved regadenoson for stress testing in conjunction with MPI. Regadenoson, unlike adenosine, is a selective A2A agonist that is given as an intravenous bolus at a fixed dose, with less undesirable side effects including atrioventricular block and bronchospasm. Unlike adenosine, regadenoson could be used in patients with mild-to-moderate reactive airway disease. This review will summarize the pre-clinical and clinical data on regadenoson, as they specifically relate to its use as a vasodilator stress agent, currently the only approved selective A2A agonist..

Original languageEnglish (US)
Pages (from-to)1123-1130
Number of pages8
JournalJournal of the American College of Cardiology
Issue number13
StatePublished - Sep 22 2009
Externally publishedYes


  • adenosine
  • myocardial perfusion imaging
  • regadenoson
  • single-photon emission computed tomography
  • stress testing

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Regadenoson: A New Myocardial Stress Agent'. Together they form a unique fingerprint.

Cite this